The CEO of Moderna lays out his vision for the company during R&D Day.
'The biggest inflection point ever': On R&D day, Moderna CEO Stéphane Bancel doubles down on vaccines and lays out a vision for a '40, 50'-drug biotech
The stakes have always been different for Moderna. They didn’t invest more in the Covid-19 vaccine race than Pfizer, Sanofi or AstraZeneca, and they didn’t have more to lose than Novavax — a $100 million biotech that became a $7 billion company virtually overnight. But they had considerably more to gain